
INNOVATIVE JOURNAL OF MEDICAL IMAGING



Mini Reveiw

Radiomics and Machine Learning in Tumor Characterization and Treatment Planning

[1]Prashant Kumar Jha*, [2]Avinash Chaubey

[1,2] Assistant Professor, Department of Allied Health Sciences, Brainware University, Kolkata, India

ABSTRACT

Recent advancements in radiomics and machine learning (ML) are revolutionizing the landscape of cancer diagnostics and treatment planning. Radiomics enables the extraction of high-dimensional quantitative features from standard medical imaging modalities such as CT, MRI, and PET, transforming non-invasive scans into data-rich resources for tumor characterization. When integrated with ML algorithms, these features can facilitate predictive modeling for tumor detection, classification, prognosis, and therapeutic response, allowing for a highly personalized approach to oncology. This integration empowers clinicians to go beyond traditional histopathology by enabling in vivo phenotyping of tumors, revealing spatial heterogeneity and biological signatures that are often missed by biopsies. Numerous studies have demonstrated the utility of radiomics in various cancer types, including glioblastoma, lung, and breast cancers, while ML models such as Support Vector Machines (SVM), Random Forests, and deep learning networks like Convolutional Neural Networks (CNNs) have shown promise in enhancing classification accuracy and treatment planning. Despite its potential, challenges such as data standardization, interpretability, and clinical validation remain critical barriers to widespread implementation. This review discusses the theoretical foundation of radiomics, ML methodologies, clinical applications in tumor characterization and treatment adaptation, and future directions including radiogenomics, real-time analytics, and accessible cloud-based platforms. Addressing these issues is essential to fully realize the transformative potential of radiomics and ML in precision oncology.

Keywords: Radiomics, Machine learning, Tunour

***Corresponding Author:** Prashant Kumar Jha, Assistant Professor, Department of Allied Health Sciences, Brainware University, Kolkata, India.

Email: prashantjee9@gmail.com

DOI: 10.62502/ijmi/898cbm72

Received: 17/07/2024 | **Accepted:** 17/08/2024 | **Published:** 30/09/2024

Copyright © 2024. The Author (s)

This is an open-access article distributed under the terms of the Creative Commons Attribution, NonCommercial- 4.0 International License (CC BY-NC-4.0), which permits noncommercial use, sharing, adaptation, and reproduction in any medium, provided the original work is properly cited and any derivative works are distributed

INTRODUCTION

The evolution of precision medicine has amplified the demand for individualized treatment strategies in oncology, as patient outcomes are profoundly influenced by the biological behavior and heterogeneity of tumors. Conventional histopathological approaches, while foundational, are invasive and may inadequately capture the spatial and molecular complexity of malignancies. [1] In response, radiomics has emerged as a transformative imaging analytics technique, offering a non-invasive solution by quantitatively extracting features such as texture, shape, and intensity from medical images. [2] These high-throughput features, when processed with advanced ML models, facilitate the identification of clinically significant patterns that may predict tumor type, aggressiveness, and therapeutic response. [3,4] Machine learning enhances the interpretive power of radiomics by managing complex, high-dimensional datasets and drawing inferences that exceed

human analytical capacity. Commonly used ML algorithms, including SVMs, Random Forests, and deep learning architectures like CNNs and Generative Adversarial Networks (GANs), have demonstrated high accuracy in classification, tumor segmentation, and survival prediction across various cancer types. [5,6] These systems support adaptive and personalized treatment planning, enabling clinicians to tailor therapies based on individual tumor phenotypes and responses. [7,8] Radiomics applications span a range of tumor types. In glioblastoma, for instance, MRI-based radiomics can predict IDH mutation status and patient survival, assisting in chemotherapy stratification. [9] In lung cancer, CT-based radiomics models have accurately identified EGFR mutation status, guiding the use of targeted therapies [10] Likewise, breast cancer radiomics has helped distinguish between triplenegative and hormone receptor-positive subtypes, enhancing treatment selection [11] Quantitative feature extraction remains central to radiomics, encompassing both first-order features (e.g., mean intensity, standard deviation) and second-order features (e.g., gray-level co-occurrence matrices), which together capture the full spectrum of tumor heterogeneity [12,13] Studies have validated the reliability of such features, with one report showing that radiomics could distinguish lung tumor subtypes with 85% accuracy [14] The integration of ML into radiomics follows a defined pipeline: data preprocessing ensures consistency across scanners and protocols, feature selection techniques like LASSO regression reduce dimensionality, and robust model training/validation approaches often involving cross-validation and external cohorts ensure generalizability [15,16]

For example, deep learning models trained on MRI datasets have achieved over 90% accuracy in predicting radiotherapy response in glioblastoma, reinforcing their clinical value. [17] Machine learning models are also being employed in treatment planning. Radiomics-guided ML can anticipate response to chemotherapy and radiotherapy, helping clinicians adjust treatment intensity or select optimal therapeutic agents. Adaptive radiotherapy, guided by dynamic imaging changes during treatment, is one such application that has reduced recurrence rates in prostate and head and neck cancers. [18,19] Similarly, in colorectal cancer, combining radiomic and clinical data improved survival prediction by more than 15%, enabling more effective risk stratification. [20] Despite significant progress, challenges persist. Imaging protocol variability across institutions impedes reproducibility, though initiatives like the Image Biomarker Standardization Initiative (IBSI) are addressing this. [21] Another concern is the interpretability of complex ML models often viewed as "black boxes." Emerging solutions from Explainable AI (XAI) aim to demystify these algorithms for clinicians. [22] Furthermore, large-scale regulatory validation is required before ML-integrated radiomics tools can achieve clinical acceptance, with ongoing multi-institutional trials providing foundational data. [23] Looking ahead, the field is moving toward radiogenomics linking imaging phenotypes with genomic signatures for deeper biological insight. Studies in glioblastoma, for instance, have demonstrated the predictive accuracy of such combined approaches. [24] Real-time image analysis is another frontier, enabling on-the-fly treatment adaptations based on evolving tumor characteristics, particularly in radiotherapy settings. [25] Additionally, cloud-based platforms are being developed to democratize access to radiomics, especially in low-resource environments [26]

Radiomics in Tumor Characterization: Radiomics in oncology begins with the extraction of a vast number of quantitative features from routinely acquired medical images such as CT, MRI, and PET scans. These features are broadly categorized into first-order statistics, which describe basic pixel intensity distributions, and higher-order statistics, which evaluate relationships between neighboring pixels to reveal patterns indicative of tumor heterogeneity. First-order features include metrics such as mean, variance, and skewness of pixel values, while second-order features involve texture measures obtained from gray-level co-occurrence or run-length matrices. These mathematical descriptors provide a comprehensive characterization of tumor morphology and behavior. Quantitative radiomic features allow differentiation between benign and malignant lesions and help classify tumor subtypes based on shape, margin sharpness, and internal texture complexity. Advanced image processing techniques segment tumors and extract features that can be used in predictive models. Combining features such as intensity distributions, edge sharpness, and texture patterns enables a robust evaluation of intratumoral heterogeneity, which is often linked to clinical outcomes like progression-free survival. For example, research has shown that radiomics could distinguish types of lung tumors with an accuracy of up to 85%, underscoring its potential as a decision-support tool in oncology. Radiomics has been applied across a spectrum of tumor types. In glioblastoma, MRI-based radiomic analyses have successfully

predicted isocitrate dehydrogenase (IDH) mutation status, which is associated with improved survival and sensitivity to chemotherapy. In lung cancer, CTderived radiomics features have accurately predicted epidermal growth factor receptor (EGFR) mutations, aiding in targeted therapy decisions. Similarly, in breast cancer, radiomic signatures have been used to differentiate between triple-negative and hormone receptor-positive tumors, enabling personalized treatment strategies tailored to tumor biology.

Machine Learning in Radiomics: Machine learning (ML) plays a transformative role in radiomics by enabling the analysis of complex, high-dimensional data derived from medical images. Through ML, patterns hidden within radiomic features can be identified and used to support tasks such as tumor classification, prognosis prediction, and treatment response assessment. Traditional supervised learning algorithms, such as Support Vector Machines (SVM), Random Forests, and logistic regression, are widely used in radiomics studies. These models are trained on labeled datasets to distinguish between disease subtypes or predict outcomes like recurrence and survival. They have proven effective across various cancer types by yielding high classification accuracy, particularly when combined with robust feature selection techniques. In recent years, deep learning approaches particularly Convolutional Neural Networks (CNNs) have gained traction due to their ability to perform automatic feature extraction and segmentation directly from imaging data. CNNs excel in handling spatial information, making them suitable for delineating tumor boundaries with high precision.

Furthermore, Generative Adversarial Networks (GANs) have emerged as valuable tools for augmenting training datasets by synthesizing realistic medical images, thereby enhancing model generalizability and robustness. The typical ML pipeline in radiomics involves several crucial steps. Initially, medical images undergo preprocessing to reduce noise and harmonize differences introduced by varied scanners and acquisition protocols. This ensures consistency across datasets, which is vital for model training. Radiomic feature extraction follows, capturing quantitative descriptors related to tumor shape, intensity, texture, and wavelet transformations. Due to the high dimensionality of radiomic data, feature selection is necessary to identify the most relevant variables while avoiding model overfitting. Techniques such as the Least Absolute Shrinkage and Selection Operator (LASSO) are frequently employed for this purpose, as they effectively reduce the feature space by penalizing less informative variables. Once the most predictive features are selected, they are used to train ML models, which are subsequently validated through crossvalidation and tested on independent external datasets. This ensures that the developed models are generalizable and reliable when applied to real-world clinical scenarios. Numerous case studies have demonstrated the efficacy of ML-integrated radiomics in oncology. In nonsmall cell lung cancer (NSCLC), CNN-based radiomic models have been successful in predicting tumor progression and metastasis, aiding in earlier therapeutic interventions. In breast cancer, ML approaches have helped forecast patient responses to neoadjuvant chemotherapy, allowing clinicians to modify treatment regimens in a timely manner. Similarly, in glioblastoma, ML models based on MRI-derived features have predicted radiotherapy response and overall survival with over 90% accuracy. These examples underscore the power of ML to extract clinically meaningful insights from imaging data, ultimately supporting personalized treatment planning and improving patient outcomes. The integration of radiomics and machine learning represents a paradigm shift in oncologic imaging, where data-driven decision-making enhances traditional diagnostic and therapeutic pathways.

DISCUSSION

The integration of radiomics and machine learning (ML) has significantly advanced the field of precision oncology by enabling quantitative analysis of medical images beyond conventional visual interpretation. Radiomic features extracted from CT, MRI, PET, and other imaging modalities capture information related to tumor shape, texture, intensity, and heterogeneity, providing valuable biomarkers for diagnosis, prognosis, and treatment planning. When combined with ML algorithms such as support vector machines, random forests, gradient boosting, and deep neural networks, these features have demonstrated high accuracy in predicting tumor histology, molecular subtypes, genetic mutations, therapeutic response, recurrence risk, and overall survival. Such predictive capabilities support personalized treatment strategies and improve clinical decision-making.

Despite these promising developments, several challenges continue to limit the widespread clinical implementation of radiomics-based ML models. Variability in imaging acquisition parameters, reconstruction techniques, segmentation methods, and feature extraction software affects the

reproducibility and reliability of radiomic biomarkers across institutions. Furthermore, the high dimensionality of radiomic datasets combined with relatively small patient cohorts increases the risk of model overfitting and reduces external validity. Robust feature selection methods, standardized imaging protocols, and large multicenter datasets are therefore essential for developing reliable predictive models.

Another important limitation is the lack of transparency associated with complex machine learning models, particularly deep learning algorithms. The "black-box" nature of these models often reduces clinician confidence and may hinder regulatory approval. Recent advances in Explainable Artificial Intelligence (XAI) have begun addressing this issue by providing interpretable visualizations and feature importance analyses that improve model transparency and clinical trust. In addition, emerging approaches such as federated learning allow institutions to collaboratively develop robust AI models without sharing sensitive patient data, thereby maintaining data privacy while enhancing model generalizability. Future research should focus on integrating radiomic features with clinical, pathological, genomic, and molecular data to develop comprehensive multimodal predictive models. Prospective multicenter validation studies, standardized reporting guidelines, and regulatory evaluation will be critical for translating radiomics-ML technologies into routine clinical oncology practice.

CONCLUSION

Radiomics combined with machine learning represents a transformative approach in precision oncology by enabling comprehensive quantitative assessment of tumor characteristics from routine medical imaging. These technologies have demonstrated considerable potential for improving tumor characterization, predicting treatment response, estimating prognosis, and supporting personalized therapeutic decision-making. However, challenges related to standardization, reproducibility, interpretability, and external validation remain significant barriers to clinical implementation. Continued advances in explainable artificial intelligence, multicenter collaborative research, standardized imaging protocols, and integration of multimodal clinical and genomic data are expected to enhance the robustness and clinical applicability of radiomics-based models. With rigorous prospective validation and appropriate regulatory approval, radiomics and machine learning are poised to become integral components of next-generation precision cancer care.

REFERENCES

1. Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48(4):441–6.
2. Kumar V, Gu Y, Basu S, Berglund A, Eschrich SA, Schabath MB, et al. Radiomics: the process and the challenges. Magn Reson Imaging. 2012;30(9):1234–48.
3. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278(2):563–77.
4. Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006.
5. Parmar C, Grossmann P, Rietveld D, Rietbergen MM, Lambin P, Aerts HJ. Radiomic machinelearning classifiers for prognostic biomarkers of head and neck cancer. Front Oncol. 2015;5:272.
6. Hosny A, Parmar C, Quackenbush J, Schwartz LH, Aerts HJ. Artificial intelligence in radiology. Nat Rev Cancer. 2018;18(8):500–10.
7. Bi WL, Hosny A, Schabath MB, Giger ML, Birkbak NJ, Mehrtash A, et al. Artificial intelligence in cancer imaging: clinical challenges and applications. CA Cancer J Clin. 2019;69(2):127–57.
8. Kickingereder P, Burth S, Wick A, Götz M, Eidel O, Schlemmer HP, et al. Radiomic profiling of glioblastoma: identifying an imaging predictor of patient survival with improved performance over established clinical and radiologic risk models. Radiology. 2016;280(3):880– 9.
9. Liu Y, Kim J, Balagurunathan Y, Li Q, Garcia AL, Stringfield O, et al. Radiomic features are associated with EGFR mutation status in lung adenocarcinomas. Clin Lung Cancer. 2016;17(5):441–8.
10. Li H, Zhu Y, Burnside ES, Drukker K, Hoadley KA, Fan C, et al. Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set. NPJ Breast Cancer. 2016;2:16012.
11. Zhang B, Tian J, Dong D, Gu D, Dong Y, Zhang L, et al. Radiomics features of multiparametric MRI as novel prognostic factors in advanced

nasopharyngeal carcinoma. Clin Cancer Res. 2017;23(15):4259–69.
12. Yip SS, Aerts HJ. Applications and limitations of radiomics. Phys Med Biol. 2016;61(13):R150–66.
13. Zwanenburg A, Vallières M, Abdalah MA, Aerts HJ, Andrearczyk V, Apte A, et al. The Image Biomarker Standardization Initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295(2):328–38.
14. Wu W, Parmar C, Grossmann P, Quackenbush J, Lambin P, Bussink J, et al. Exploratory study to identify radiomics classifiers for lung cancer histology. Front Oncol. 2016;6:71.
15. Parmar C, Velazquez ER, Leijenaar RT, Jermoumi M, Carvalho S, Mak RH, et al. Robust radiomics feature quantification using semiautomatic volumetric segmentation. PLoS One. 2014;9(7):e102107.
16. Aerts HJ, Rios Velazquez E, Leijenaar R, Parmar C, Grossmann P, Carvalho S, et al. Defining the radiomic feature reproducibility. Nat Commun. 2014;5:4006.
17. Lao J, Chen Y, Li ZC, Li Q, Zhang J, Liu J, et al. A deep learning-based radiomics model for prediction of survival in glioblastoma multiforme. Sci Rep. 2017;7:10353.
18. Jethanandani A, Lin TA, Volpe S, Switchenko JM, Landry JC, Higgins KA, et al. Exploring applications of radiomics in magnetic resonance imaging of head and neck cancer: a systematic review. Front Oncol. 2018;8:131.
19. van Dijk LV, Van den Bosch L, Al-Mamgani A, Spasiano R, Crezee J, Zuur CL, et al. Improving patient selection for adaptive radiotherapy of head and neck cancer by including information from pretreatment PET-CT and CT scans. Radiother Oncol. 2020;142:124–31.
20. Wang Y, Liu W, Yu Y, Liu T, Song L, Dong Z, et al. Predicting survival in patients with colorectal cancer using CT radiomics: a radiomics signature. Cancer Med. 2019;8(9):4085–92.
21. Zwanenburg A, Leger S, Vallières M, Löck S. Image biomarker standardisation initiative. arXiv preprint. 2016;arXiv:1612.07003.
22. Holzinger A, Langs G, Denk H, Zatloukal K, Müller H. Causability and explainability of artificial intelligence in medicine. Wiley Interdiscip Rev Data Min Knowl Discov. 2019;9(4):e1312.
23. 23. Gillies RJ, Schabath MB. Radiomics improves cancer screening and early detection. Cancer Imaging Arch. 2021;21(1):8.
24. Itakura H, Achrol AS, Mitchell LA, Loya JJ, Liu T, Westbroek EM, et al. Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities. Sci Transl Med. 2015;7(303):303ra138.
25. Tseng HH, Luo Y, Cui S, Chien JT, Ding H, Chang JT, et al. Deep learning-based prediction of treatment response and survival outcomes from PET images in non–small cell lung cancer. Clin Cancer Res. 2021;27(3):821–9.
26. Bhargava HK, Ghosh S, Foltz JR, Christodoulou E, Knoll F, Recht MP, et al. Cloud computing and artificial intelligence in radiology: opportunities and challenges. Radiology: Artificial Intelligence. 2020;2(6):e190017.

How to cite: Jha PK, Chaubey A. Radiomics and Machine Learning in Tumor Characterization and Treatment Planning. Innov. J. Med. Imaging 2024;1(2):16-20. doi: 10.62502/ijmi/898cbm72